A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 815 participants.

Also called NCT07026968

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 815 participants (planned count) (from the registry)
Sponsor
CSPC Ouyi Pharmaceutical Co., Ltd. (from the registry)
Registry
  • NCT NCT07026968
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07026968. Randomized; double masking; primary purpose treatment. Start 2025-06-20 (actual); primary completion 2026-10-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes
Intervention (Drug)
Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR
Intervention (Drug)
Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR
Intervention (Drug)
Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR
Intervention (Drug)
Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR
Intervention (Drug)
Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XR
Lead sponsor
CSPC Ouyi Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07026968
Content hash
b17534c12d04b8458ed9409fce0f6b768fdbd9dda8ae665d9a87360957ff5efa